Yervoy (ipilimumab) / BMS 
Welcome,         Profile    Billing    Logout  
 197 Diseases   398 Trials   398 Trials   21826 News 


«12...1819202122232425262728...266267»
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion date, Trial primary completion date:  INFLUENCE: Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer. (clinicaltrials.gov) -  Mar 2, 2024   
    P2,  N=19, Active, not recruiting, 
    Trial primary completion date: Mar 2024 --> Mar 2025 Trial completion date: Oct 2023 --> Apr 2024 | Trial primary completion date: Jun 2023 --> Oct 2023
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Review, Journal, Checkpoint inhibition:  Perimyocarditis Associated with Immune Checkpoint Inhibitors: A Case Report and Review of the Literature. (Pubmed Central) -  Feb 28, 2024   
    After hospitalization, her cardiac condition was successfully resolved with corticosteroids, colchicine, and symptomatic treatment. To the best of our knowledge, this is one of the rarest cases to be reported of perimyocarditis as a toxicity of immunotherapy in a patient treated for adenocarcinoma of the lung.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Review, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker, Metastases:  Immune checkpoint inhibitors in metastatic melanoma therapy (Review). (Pubmed Central) -  Feb 27, 2024   
    Concerns regarding the development of resistance to ICIs also warrant attention. The present review summarizes and discusses the advent of ICIs with a marked significant breakthrough in the treatment of metastatic melanoma, providing improved outcomes compared to traditional therapies.
  • ||||||||||  SQZ-AAC-HPV / STEMCELL Technologies
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Monotherapy, Checkpoint inhibition:  ENVOY-001: Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) -  Feb 23, 2024   
    P1,  N=5, Terminated, 
    Recruiting --> Active, not recruiting N=72 --> 5 | Trial completion date: Apr 2024 --> Nov 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2024 --> Nov 2023; Corporate Decision
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial termination:  Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) (clinicaltrials.gov) -  Feb 22, 2024   
    P2,  N=4, Terminated, 
    Active, not recruiting --> Terminated; cfDNA screening data found that the prevalence of POLE/POLD1 mutations was lower than expected. It was determined that there are no feasible options to amend this study in a fashion that would not be duplicative of other currently accruing trials.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion date, Trial primary completion date:  Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer (clinicaltrials.gov) -  Feb 20, 2024   
    P2,  N=137, Active, not recruiting, 
    It was determined that there are no feasible options to amend this study in a fashion that would not be duplicative of other currently accruing trials. Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025
  • ||||||||||  Cubicin (daptomycin) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Immunotherapy Induced Encephalitis (San Diego Convention Center, Area K (Hall H, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_6034;    
    Admitting physicians along with sub-specialists including infectious diseases, oncologists, and neurologists need to be aware of the clinical presentation of serious but uncommon neurologic adverse effects associated with checkpoint inhibitors. Prompt diagnosis and management are critical to minimize serious complications and patient outcomes.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    De Novo Metastatic Melanoma Presenting Like Guillain-Barr (San Diego Convention Center, Area E (Hall A-B2, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_5958;    
    With the patient not improving on goal directed therapy for Guillain Barre Syndrome the importance of reassessing the workup, including imaging can lead to new differential diagnosis, resulting in a refocused workup and definitive diagnosis. With the increasing incidence, this case aids in the advancement of the literature in cases requiring ICU level care.
  • ||||||||||  Yervoy (ipilimumab) / BMS
    Reengaging CD8+ T Cells in Clearance of Senescent Cells in Lung Injury Repair (San Diego Convention Center, Room 2 (Upper Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_5302;    
    This is associated with an increased number of Cd3+ T cells, indicating a role for CTLA4 targeting of cytotoxic T cells to accelerate clearance of senescent T cells in this murine lung injury model. These findings support the notion that CD8+ T cells targeted immunotherapeutic strategies could be beneficial in IPF.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    A Puzzling Pathology: A Rare Presentation of Lung Adenocarcinoma (San Diego Convention Center, Area J (Hall H, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_4541;    
    Vasculitis and atypical infections, such as melioidosis were higher on the differential, however she did not respond to intravenous meropenem...After discussion at multi-disciplinary care conference, she was started on ipilimumab/nivolumab/carboplatin/pemetrexed for unresectable adenocarcinoma...The possible congenital malformation or prior cystic lesion was certainly not identified prior to these repeated presentations, and she did not have recurrent issues with pneumonias or a chronic cough. This case highlights the need to maintain a high degree of suspicion for atypical presentations of adenocarcinoma and pursuing earlier invasive testing with progressive structural changes.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Synchronous Lung and Colon Cancer: Multidisciplinary Challenges (San Diego Convention Center, Area J (Hall H, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_4517;    
    In metastatic colon cancer, immune checkpoint inhibitors such as nivolumab, ipilimumab, and pembrolizumab have been approved for use. Further studies are required to explore novel treatment strategies that could potentially improve the survival outcomes for patients with synchronous or metachronous lung and colon cancer As we strive to unravel the intricacies of such cases, this report serves as a poignant reminder of the ongoing quest to improve the outcomes for patients facing these rare and challenging clinical scenarios.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Unilateral Pleural Effusion: A Rare Case of Malignant Mesothelioma With Positive Rheumatoid Serology (San Diego Convention Center, Area G (Hall A-B2, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_2239;    
    Considering the unfavorable outcomes associated with late diagnosis of mesothelioma, it is crucial to expedite the diagnostic process. Further research is necessary to understand the underlying mechanisms that may connect mesothelioma and autoimmune diseases, potentially contributing to improved patient diagnosis and outcomes.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Primary Pleural Leiomyosarcoma Presenting as a Large Pleural Effusion (San Diego Convention Center, Area G (Hall A-B2, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_2227;    
    Limited data exists on the efficacy of immune checkpoint inhibitors, although they were continued in our case due to tumor response. Primary Hepatic Leiomyosarcoma usually presents as a solitary mass, with multiple small masses usually due to metastatic disease.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Sarcoid Type Mediastinal Limphadenopathy in Patients Treated With Immunotherapy: Clinical Characteristics and Prognostic Significance (San Diego Convention Center, Room 30C-E (Upper Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_796;    
    Clinical course in most was towards resolution, with or without discontinuation of ICIs, low need for systemic steroids, unlike what was observed in idiopathic sarcoidosis, where asymptomatic patients are lower, the proportion of patients who progress is higher and the need for steroids/immunosuppression is greater, with a longer resolution time. Prospective and collaborative studies are needed to consolidate data.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion, Trial completion date, Trial primary completion date:  RACIN in Patients With Advanced TIL-negative Solid Tumors (clinicaltrials.gov) -  Feb 20, 2024   
    P1,  N=40, Completed, 
    Prospective and collaborative studies are needed to consolidate data. Active, not recruiting --> Completed | Trial completion date: Mar 2022 --> Oct 2023 | Trial primary completion date: Mar 2022 --> Oct 2023
  • ||||||||||  Imlygic (talimogene laherparepvec) / Amgen
    Phase classification:  Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma (clinicaltrials.gov) -  Feb 20, 2024   
    P1/2,  N=217, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Mar 2022 --> Oct 2023 | Trial primary completion date: Mar 2022 --> Oct 2023 Phase classification: P1b/2 --> P1/2
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial termination, Checkpoint inhibition:  CPIT-002: Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (clinicaltrials.gov) -  Feb 19, 2024   
    P1,  N=8, Terminated, 
    Future studies are warranted to elucidate these associations. Active, not recruiting --> Terminated; Lack of Enrollment
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca, Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal, PD(L)-1 Biomarker, IO biomarker:  Effect of CTLA-4 Inhibition on Inflammation and Apoptosis After Spinal Cord Injury. (Pubmed Central) -  Feb 17, 2024   
    Furthermore, the combination therapy with ipilimumab and durvalumab after SCI had more pronounced effects than treatment with either inhibitor alone. These findings indicate that CTLA-4 contributes to neuroinflammation and apoptosis after SCI, presenting a promising new therapeutic target for this traumatic condition.
  • ||||||||||  Tecentriq (atezolizumab) / Roche, Yervoy (ipilimumab) / Ono Pharma, BMS
    Trial completion date:  ImmunoPET With an Anti-CD8 Imaging Agent (clinicaltrials.gov) -  Feb 15, 2024   
    P1/2,  N=47, Active, not recruiting, 
    Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024 Trial completion date: Dec 2023 --> Dec 2024